Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer Pamela Samson, MD, MPHS, Traves.

Slides:

Advertisements

Similar presentations

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Advertisements

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Comparison of Video-Assisted Thoracoscopic Surgery and Robotic Approaches for Clinical Stage I and Stage II Non-Small Cell Lung Cancer Using The Society.

Evaluation of the Reliability of Clinical Staging of T2 N0 Esophageal Cancer: A Review of The Society of Thoracic Surgeons Database Traves D. Crabtree,

Endoscopic Ultrasound for Early Stage Esophageal Adenocarcinoma: Implications for Staging and Survival Traves D. Crabtree, MD, Wael N. Yacoub, MD, Varun.

Chun Chieh Lin, PhD, MBA, Matthew P

Joshua E. Rosen, BASc, Hari B

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer? Traves D. Crabtree, MD, Varun Puri,

Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Nirav S. Kapadia, MD, MS, Luca F. Valle, MD, Julie A

Diaphragmatic Defect Complicating Peritoneal Dialysis

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients Elizabeth A. David, MD, Stina W. Andersen, PhD,

Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy

Castigliano M. Bhamidipati, DO, MS, George J

Operative Results and Outcomes in Children With Shone's Anomaly

National Patterns of Care and Outcomes After Combined Modality Therapy for Stage IIIA Non–Small-Cell Lung Cancer Aalok P. Patel, BS, Traves D. Crabtree,

Andrea S. Wolf, MD, MPH, Scott J

Philip W. Smith, MD, Hongkun Wang, PhD, Leo M. Gazoni, MD, K

Chris Dickhoff, MD, Max Dahele, MD, PhD, Sayed M

Varun Puri, MD, Andrew Tran, MS, Jennifer M. Bell, BS, Traves D

Positron Emission Tomography-Computed Tomography for Postoperative Surveillance in Non-Small Cell Lung Cancer Se Hoon Choi, MD, Young Tae Kim, MD, PhD,

Felix G. Fernandez, MD, Chadrick E. Denlinger, MD, G

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer Usman Ahmad, MD, Traves D. Crabtree,

Lung Cancer Surgery in Patients With Liver Cirrhosis

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene.

The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis Pamela Samson, MD, Aalok Patel, BS,

Tara R. Semenkovich, MD, MPHS, Christine Frederiksen, MS, Jessica L

Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival Pamela Samson, MD, MPHS, Traves.

The National Surgical Quality Improvement Program risk calculator does not adequately stratify risk for patients with clinical stage I non–small cell.

Survival After Lobectomy Versus Segmentectomy for Stage I Non-Small Cell Lung Cancer: A Population-Based Analysis Bryan A. Whitson, MD, PhD, Shawn S.

Use of Amiodarone After Major Lung Resection

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

Impact of Blood Product Transfusion on Short and Long-Term Survival After Cardiac Surgery: More Evidence Balu Bhaskar, MD, FCICM, Joel Dulhunty, PhD,

Abel Gómez-Caro, MD, Pedro Arguis, MD The Annals of Thoracic Surgery

Treatment Outcomes in Stage I Lung Cancer

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Extent of Lymphadenectomy Is Associated With Improved Overall Survival After Esophagectomy With or Without Induction Therapy Pamela Samson, MD, MPHS,

Mara B. Antonoff, MD, Varun Puri, MD, Bryan F

Office-Based Spirometry: A New Model of Care in Preoperative Assessment for Low- Risk Lung Resections Jessica L. Hudson, MD, MPHS, Jennifer M. Bell, BSN,

William M. Whited, MD, Paul Henley, BS, Erin M

Adhering to Quality Measures in Esophagectomy Is Associated With Improved Survival in All Stages of Esophageal Cancer Pamela Samson, MD, MPHS, Varun.

Stephen R. Broderick, MD, MPHS, Aalok P. Patel, BS, BA, Traves D

Mara B. Antonoff, MD, Wayne L. Hofstetter, MD, Arlene M

Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer? Anna Lee, MD, MPH, Andrew T.

Shared Decision Making and Effective Risk Communication in the High-Risk Patient With Operable Stage I Non-Small Cell Lung Cancer Pamela Samson, MD,

Patterns of care in hilar node-positive (N1) non–small cell lung cancer: A missed treatment opportunity? Matthew J. Bott, MD, Aalok P. Patel, BS, Vivek.

Prognostic Heterogeneity in Multilevel N2 Non-Small Cell Lung Cancer Patients: Importance of Lymphadenopathy and Occult Intrapulmonary Metastases Yukinori.

Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer Pamela Samson, MD, Aalok Patel,

Neoadjuvant Chemoradiation Therapy Is Beneficial for Clinical Stage T2 N0 Esophageal Cancer Patients Due to Inaccurate Preoperative Staging Jennifer.

Lobectomy versus stereotactic body radiotherapy for stage I non–small cell lung cancer: Post hoc analysis dressed up as level-1 evidence? Bryan F. Meyers,

Varun Puri, MD, Yinin Hu, MS, Tracey Guthrie, RN, Traves D

Clinical Outcome After Pulmonary Resection for Lung Cancer Patients on Hemodialysis Toshiro Obuchi, MD, Wakako Hamanaka, MD, Yasuhiro Yoshida, MD, Jun.

Yinin Hu, MD, Timothy L. McMurry, PhD, Kristen M. Wells, PhD, James M

Treatment of Malignant Pleural Effusion: A Cost-Effectiveness Analysis

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Mark I. Block, MD The Annals of Thoracic Surgery

Spencer J. Melby, MD, Shane J. Larue, MD, John M

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Induction Therapy Followed by Surgery for T3-T4/N0 Non-Small Cell Lung Cancer: Long-Term Results Filippo Lococo, MD, Alfredo Cesario, MD, Stefano Margaritora,

Induction Chemoradiation Is Not Superior to Induction Chemotherapy Alone in Stage IIIA Lung Cancer Asad A. Shah, MD, Mark F. Berry, MD, Ching Tzao, MD,

Adjuvant Therapy for Node-Positive Esophageal Cancer After Induction and Surgery: A Multisite Study Tara R. Semenkovich, MD, MPHS, Melanie Subramanian,

Presentation transcript:

Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer Pamela Samson, MD, MPHS, Traves D. Crabtree, MD, Cliff G. Robinson, MD, Daniel Morgensztern, MD, Stephen Broderick, MD, A. Sasha Krupnick, MD, Daniel Kreisel, MD, PhD, G. Alexander Patterson, MD, Bryan Meyers, MD, MPH, Varun Puri, MD, MSCI The Annals of Thoracic Surgery Volume 103, Issue 4, Pages 1070-1075 (April 2017) DOI: 10.1016/j.athoracsur.2016.09.053 Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Histogram of clinical stage IIIA NSCLC patients in the NCDB from 2006 to 2012, by length of time between start of induction therapy and date of surgical resection.StartYear 1Year 2Year 3Year 4Year 5Early surgery85163235120310335Delayed surgery1,5291,09457530912931 The Annals of Thoracic Surgery 2017 103, 1070-1075DOI: (10.1016/j.athoracsur.2016.09.053) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Kaplan-Meier analysis for clinical stage IIIA non-small cell lung cancer patients, by early versus delayed interval from the start of induction therapy to date of surgery.StartYear 1Year 2Year 3Year 4Early surgery946637165Delayed surgery94642060 The Annals of Thoracic Surgery 2017 103, 1070-1075DOI: (10.1016/j.athoracsur.2016.09.053) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 3 Kaplan-Meier analysis for clinical stage IIIA non-small cell lung cancer patients with positive surgical margins (≥R1), by early versus delayed interval from the start of induction therapy to date of surgery. The Annals of Thoracic Surgery 2017 103, 1070-1075DOI: (10.1016/j.athoracsur.2016.09.053) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions